Author’s response to reviews

Title: San Huang Shel Shin Tang beta-cyclodextrin complex augmented the hepatoprotective effects against carbon tetrachloride-induced acute hepatotoxicity in rats

Authors:

Yu-Lan Yeh (1867@cch.org.tw)
Wei-Jen Ting (tim_sigeen@hotmail.com)
Dennis Jine-Yuan Hsieh (djh@csmu.edu.tw)
Hsi-Hsien Hsu (u596@mmc.edu.tw)
Yueh-Min Lin (YuehMinLin@outlook.com)
Chia-Yao Shen (x00003061@meiho.edu.tw)
Chung-Ho Chang (changch@nhri.org.tw)
Viswanadha Vijaya Padma (padma.vijaya@gmail.com)
Yuhsin Tsai (yhtsai@mail.cmu.edu.tw)
Chih-Yang Huang (cyhuang@mail.cmu.edu.tw)

Version: 9 Date: 11 April 2016

Author’s response to reviews:

Dear editor Dr. Tom,

My revising manuscript was refined according to associate editor’s comments and editorial comments. One author of our team was changed back to Mrs. Yeh in revising manuscript, who is original first author.

All changes in revising manuscript are addressed with yellow labeling color. The point-by-point response to the concerns is listed as follow:

Responds to associate editor comments:

Ln 67 “to” treat
Respond: The word was change to “to” in revised manuscript. (Line 66)

Ln 178 But AST and ALT were expressed significantly after 179 CCl4-IP treatment within ….to….AST and ALT were significantly expressed after
Respond: The sentence was change to “AST and ALT were significantly expressed after” in revised manuscript. (Line 177)

Ln 180 Especially, ATL 9 expressions were reduced in SHSST, SHSSTc and silymarin treatment groups, but AST expression only can be reduced in SHSSTc treatment group….ATL9 expression was especially reduced in SHSST, SHSSTc and silymarin treatment groups while AST expression was reduced only in the SHSSTc treatment group.
Respond: The sentence was change to “ATL9 expression was especially
reduced in SHSST, SHSSTc and silymarin treatment groups while AST expression was reduced only in the SHSSTc treatment group.” in revised manuscript. (Line 179)

196 In SHSSTc and silymarin treatments, the TGF-# pathway protein expression was decreased and similar to the control group, but unmodified SHSST treatments did not reduce TGF-# pathway protein expression significantly…. The TGF-# pathway protein expression showed a decrease in the SHSSTc and silymarin treated groups similar to the control group. The unmodified SHSST treated group did not show a significant reduction in TGF-# pathway protein expression.

Respond: The sentence was change to “The TGF-# pathway protein expression showed a decrease in the SHSSTc and silymarin treated groups similar to the control group. The unmodified SHSST treated group did not show a significant reduction in TGF-# pathway protein expression.” in revised manuscript. (Line 193)

Responds to editorial comments:

Please include a "Declarations" section at the end of your manuscript. Contained within this section should be a list of abbreviations, as well as sections on 'Ethics approval and consent to participate', 'consent for publication', 'Availability of data and materials', Competing interests', 'Funding', 'Authors' Contributions' and 'Acknowledgements'. In the event that any of these sections are not relevant for your study, we would still ask you to include them, but to include a statement detailing that this information is not relevant. Further details on the information that should be included in your "Declarations" section, as well as how to format it, can be found in our submission guidelines (http://bmccomplementalternmed.biomedcentral.com/submission-guidelines/research-article).

Respond: The “Declarations” was added in the end of revised manuscript.